Postexposure Prophylaxis for Hepatitis B
The Centers for Disease Control and Prevention (CDC) estimates that between 800,000 and 1.4 million people in the United States are currently infected with hepatitis B. Stop the threat with HyperHEP B® S/D (hepatitis B immune globulin [human]).1
For more information, recommendations, and guidelines concerning hepatitis B, visit the CDC Advisory Committee on Immunization Practices (ACIP).
Vaccines can take weeks to build immunity but can protect for years.2 HyperHEP B S/D provides immediate protection. This allows the vaccine the time needed to establish active immunity in high-risk situations, such as1:
- Patients exposed to blood containing hepatitis B surface antigen (HBsAg)
- Perinatal exposure of infants born to HBsAg-positive and/or hepatitis B envelope antigen–positive mothers1
- Sexual exposure to an HBsAg-positive person
- Household exposure to persons with acute HBV
Immediate Protection
HyperHEP B S/D contains high titers of hepatitis B antibodies for postexposure prophylaxis, providing rapid immune protection with detectable levels of antibodies that persist for approximately 2 months or longer. When used in combination with a vaccine, a hepatitis B immune globulin such as HyperHEP B S/D offers maximum postexposure immune protection.1,3
According to the CDC, immune globulins like HyperHep S/D, when used in combination with a vaccine, can prevent the spread of hepatitis B by as much as 75%.4
Safety Is a Priority3
- HyperHEP B S/D is mercury (thimerosal) free and latex free
- HyperHEP B S/D has Food and Drug Administration (FDA) labeling for capacity to remove pathogenic prions that may cause transmissible spongiform encephalopathies in humans
- Studies of the HyperHEP S/D manufacturing process demonstrated that TSE clearance is achieved during the Pooled Plasma to Effluent III Fraction Process (6.7 log10). These studies provide reasonable assurance that low levels of Creutzfeldt-Jakob disease (CJD) or variant CJD agent infectivity, if present in the starting material, would be removed
- HyperHEP B S/D offers tamper-evident packaging and incorporates
UltraSafe® Needle Guards to help protect the healthcare professional from needlestick injuries - Because HyperHEP B S/D is made from human plasma, it may carry a risk of transmitting infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob Disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products
Dosing Recommendations3

Product Information3
